Allergy Therapeutics (LON:AGY) Stock Price Down 7% – Time to Sell?

Shares of Allergy Therapeutics plc (LON:AGY) were down 7% during mid-day trading on Wednesday . The stock traded as low as GBX 5.73 ($0.07) and last traded at GBX 6 ($0.08). Approximately 178,716 shares were traded during trading, a decline of 54% from the average daily volume of 386,971 shares. The stock had previously closed at GBX 6.45 ($0.08).

Allergy Therapeutics Price Performance

The company has a 50 day moving average of GBX 6.57 and a 200 day moving average of GBX 5.92. The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The stock has a market capitalization of £280.16 million, a price-to-earnings ratio of -5.49, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY) last released its earnings results on Monday, March 31st. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%. As a group, equities research analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.